NewAmsterdam Pharma Company N.V. is a biopharmaceutical company dedicated to designing, developing, and commercializing transformative therapies for cardiometabolic diseases. With a focus on addressing significant unmet medical needs, NewAmsterdam Pharma’s primary function is to create innovative treatments that can improve patient outcomes and quality of life. The company operates at the intersection of scientific research and clinical application, leveraging cutting-edge technology and in-depth scientific knowledge to advance its drug pipeline. NewAmsterdam Pharma's initiatives are crucial in the healthcare sector, focusing on developing medications that target conditions related to lipid metabolism disorders, which have widespread implications for public health. By pioneering novel approaches to treatment, NewAmsterdam Pharma plays a significant role in the pharmaceutical market, striving to provide impactful therapies that can make a considerable difference in managing chronic and life-threatening diseases. The company's efforts not only contribute to advancements in medical science but also hold potential economic significance through partnerships, regulatory milestones, and product launches.
WebsiteGooimeer 2-35
Naarden, 1411 DC
Netherlands
- SPINOZA is studying obicetrapib in adults with biomarker evidence suggestive of preclinical Alzheimer’s disease who do not have noticeable memory or functional symptoms- - The study will evaluate changes in blood-based biomarkers associated with Alzheimer’s disease, including p-tau 217, and additional cognitive and functional measures- NAARDEN, the Netherlands and MIAMI, Sept. 29, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a lat
NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) has cleared a major regulatory hurdle. On September 21, it announced European Commission approval of Ubeslo, containing 10 mg of obicetrapib, and Evlarco, combining 10 mg of obicetrapib with 10 mg of ezetimibe. These are the products’ first global approvals. The medicines lower low-density lipoprotein cholesterol, or LDL-C, commonly called […]
NewAmsterdam Pharma has delivered a powerful long term share price gain, yet the recent pullback raises a sharper question for investors about how its current market value lines up with the company’s book value. With the stock now some distance below its earlier highs, the issue is whether the balance sheet still backs up where the price sits today. Over the past 3 years, NewAmsterdam Pharma has returned about 139%, which now puts real pressure on the numbers to show that book value keeps...
Investors talking about NAMSW also mention
| # | Name | Attention |
|---|---|---|
| 1 | NewAmsterdam Pharma Company N.V.NAMS | 0%+0 |
| 2 | Tesla, Inc.TSLA | 5.8%-1.93 |
| 3 | DogecoinDOGE | 0.02%-0.01 |
What share of all stock conversation is about NAMSW?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Attention | 0% new | 0% new | 0% new | 0% +0 |
Of the messages about NAMSW that take a side, what share is each?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Bullish | — | — | — | 100% new | ||
| Bearish | — | — | — | 0% -100 |
Of the messages about NAMSW that carry a topic, what share is each?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Announcements | 100% | 100% | 100% | 9.73% | ||
| Analysts | 0% | 0% | 0% | 45.13% | ||
| Controversies | 0% | 0% | 0% | 0% | ||
| Earnings | 0% | 0% | 0% | 0% | ||
| Macro | 0% | 0% | 0% | 45.13% | ||
| Technical Analysis | 0% | 0% | 0% | 0% |
Of the messages about NAMSW, what share comes from each group?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Regulars | 0% | 0% | 0% | 0% | ||
| Newcomers | 100% | 100% | 100% | 100% |